Correction: High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways

Correction to “High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways” by Gerges A and Canning U. Explor Drug Sci. 2025;3:1008109. DOI: 10.37349/eds.2025.1008109. The authors have recognized an error in the published paper. This correction does not affect the scientific content, interpretation of the results, or the conclusions of the paper. The authors apologize for any inconvenience caused to the readers by this error. The original uncorrected PDF can be accessed from https://www.explorationpub.com/uploads/1008109_1st.pdf.

Authors

Institutions

Publication Details

Journal
Exploration of Drug Science
Published
2026-01-09
DOI
https://doi.org/10.37349/eds.2026.1008142
Primary Topic
Neuroblastoma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correction: High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways

Amgad Gerges, Una Canning
Exploration of Drug Science
Neuroblastoma Research and Treatments
article

Correction: High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways

Amgad Gerges, Una Canning
article en

Abstract

Correction to “High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways” by Gerges A and Canning U. Explor Drug Sci. 2025;3:1008109. DOI: 10.37349/eds.2025.1008109. The authors have recognized an error in the published paper. This correction does not affect the scientific content, interpretation of the results, or the conclusions of the paper. The authors apologize for any inconvenience caused to the readers by this error. The original uncorrected PDF can be accessed from https://www.explorationpub.com/uploads/1008109_1st.pdf.

Exploration of Drug ScienceVol. 4
London Metropolitan University (GB), Independent Age (GB)
Openalex Percentile: Top 92%
Neuroblastoma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Correction: High-risk neuroblastoma stage 4 (NBS4): multi-target inhibitors for c-Src kinases (Csk) and retinoic acid (RA) signalling pathways — Amgad Gerges, Una Canning · Exploration of Drug Science (2026) | TGRS Research Map | TGRS